Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy

Journal of Korean Medical Science

Volumn 23, Issue 5, 2008, Pages 852-856

  Choi, Chan Bum ^a   Kim, Tae Jong ^a   Park, Hee Jin ^a   Uhm, Wan Sik ^a   Jun, Jae Bum ^a   Bae, Sang Cheol ^a   Yoo, Dae Hyun ^a   Kim, Tae Hwan ^a  

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

Ankylosing; Clinical effectiveness; Safety; Spondylitis; TNFR Fc fusion protein

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; KOREA; MALE; METABOLISM; PROSPECTIVE STUDY; QUALITY OF LIFE; REMISSION; TREATMENT OUTCOME;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KOREA; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 56049116501     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.5.852     Document Type: Article

References (32)

1. Ahearn JM, Hochberg MC. Epidemiology and genetics of ankylosing spondylitis. J Rheumatol Suppl 1988; 16: 22-8.
2. Lee JH, Jun JB, Jung S, Bae SC, Yoo DH, Kim TY, Kim SY, Kim TH. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002; 17: 669-73.
3. Boonen A, van der Heijde D, Landewe R, Guillemin F, Rutten-van Molken M, Dougados M, Mielants H, de Vlam K, van der Tempel H, Boesen S, Spoorenberg A, Schouten H, van der Linden S. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62: 732-40.
4. Sturrock RD, Hart FD. Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 1974; 33: 129-31.
5. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006; 33: 722-31.
6. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2004: CD002822.
7. Crew MD, Effros RB, Walford RL, Zeller E, Cheroutre H, Brahn E. Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res 1998; 18: 219-25.
8. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, Molina R, Ballesta A, Munoz-Gomez J. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-31.
9. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
10. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 1349-56.
11. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-600.
12. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
13. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
15. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
16. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-8.
17. Kim MH, Cho YS, Uhm WS, Kim S, Bae SC. Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res 2005; 14: 1401-6.
18. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44: 1876-86.
19. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1438-44.
20. Korea Food and Drug Administration. Guideline for the treatment of latent tuberculosis in patients receiving biologic agents. 2004. Available online at http://www.kfda.go.kr
21. Yun JH, Kang JM, Kim KS, Kim SH, Kim TW, Park YW, Sung YK, Sohn JH, Song BJ, Uhm WS, Yoon HJ, Lee OY, Lee JH, Lee CB, Lee CH, Jung WT, Choe JY, Choi HS, Han DS, Bae SC. Health-related quality of life in Korean patients with chronic diseases. J Korean Rheum Assoc 2004; 11: 263-74.
22. Seong SS, Choi CB, Sung YK, Park YW, Lee HS, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee OY, Bae SC. Health-related quality of life using EQ-5D in Koreans. J Korean Rheum Assoc 2004; 11: 254-62.
23. Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005; 44: 342-8.
24. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.
25. Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005; 53: 856-63.
26. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67.
27. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
28. Jauregui E, Conner-Spady B, Russell AS, Maksymowych WP. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. J Rheumatol 2004; 31: 2422-8.
29. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
30. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-70.
31. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
32. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, Carreno L, Figueroa M. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.